Digestive Diseases and Sciences

, Volume 55, Issue 4, pp 911–919 | Cite as

Preventive Effects of Different Probiotic Formulations on Travelers’ Diarrhea Model in Wistar Rats

Preventive Effects of Probiotics on TD
  • Jean-François BissonEmail author
  • Sophie Hidalgo
  • Pascale Rozan
  • Michaël Messaoudi
Original Article


A new animal model of travelers’ diarrhea has been developed by infecting rats orally with a strain of enterotoxigenic Escherichia coli in order to assess the efficacy of three probiotic formulations for the prevention of travelers’ diarrhea. Five groups of six rats were given daily (by oral gavage) either a placebo (negative and positive control groups), the suspension of bacterial probiotics called FF1, the yeast probiotic Saccharomyces boulardii, or a combination of both, called ProtecflorTM. After 14 days of treatment, all groups except the negative control one were infected by oral administration of E. coli. Body temperature, body weight, food and water consumption, stools consistency, behavior, and cytokines secretion were disturbed following E. coli infection. Probiotics-treated groups generally displayed less-pronounced symptoms, the combination of probiotics ProtecflorTM being the most effective.


Travelers’ diarrhea Escherichia coli Prevention Probiotics Rat 



We would like to thank Lallemand SAS France for the sponsoring this study and for the supply of probiotic samples.


  1. 1.
    Yates J. Traveler’s diarrhea. Am Fam Physician. 2005;71:2095–2100.PubMedGoogle Scholar
  2. 2.
    Castelli F, Saleri N, Tomasoni LR, Carosi G. Prevention and treatment of traveller’s diarrhea. Focus on antimicrobial agents. Digestion. 2006;73:109–118. doi: 10.1159/000089786.CrossRefPubMedGoogle Scholar
  3. 3.
    Guarner F, Matagelada JR. Gut flora in health and disease. Lancet. 2003;361:512–519. doi: 10.1016/S0140-6736(03)12489-0.CrossRefPubMedGoogle Scholar
  4. 4.
    Roe AJ, Gally DL. Enteropathogenic and enterohemorrhagic Escherichia coli and diarrhoea. Curr Opin Infect Dis. 2000;13:511–517. doi: 10.1097/00001432-200010000-00013.CrossRefPubMedGoogle Scholar
  5. 5.
    Diemert DJ. Prevention and self-treatment of traveler’s diarrhea. Clin Microbiol Rev. 2006;19:583–594. doi: 10.1128/CMR.00052-05.CrossRefPubMedGoogle Scholar
  6. 6.
    DuPont HL. Therapy for and prevention of traveler’s diarrhea. Clin Infect Dis. 2007;45:78–84. doi: 10.1086/518155.CrossRefGoogle Scholar
  7. 7.
    Billoo AG, Memon MA, Khaskheli SA, et al. Role of a probiotic (Saccharomyces boulardii) in management and prevention of diarrhoea. World J Gastroenterol. 2006;12:4557–4560.PubMedGoogle Scholar
  8. 8.
    Huebner ES, Surawicz CM. Probiotics in the prevention and treatment of gastrointestinal infections. Gastroenterol Clin North Am. 2006;35:355–365. doi: 10.1016/j.gtc.2006.03.005.CrossRefPubMedGoogle Scholar
  9. 9.
    Yan F, Polk DB. Probiotics as functional food in the treatment of diarrhea. Curr Opin Clin Nutr Metab Care. 2006;9:717–721. doi: 10.1097/01.mco.0000247477.02650.51.CrossRefPubMedGoogle Scholar
  10. 10.
    Johnson-Henry KC, Riff JD, Gordanpour M, Sherman PM. Probiotics in models of gastrointestinal infections. Nutrafoods. 2005;4:29–36.Google Scholar
  11. 11.
    Medici M, Vinderola CG, Weill R, Perdigon G. Effect of fermented milk containing probiotic bacteria in the prevention of an enteroinvasive Escherichia coli infection in mice. J Dairy Res. 2005;72:243–249. doi: 10.1017/S0022029905000750.CrossRefPubMedGoogle Scholar
  12. 12.
    Martins FS, Nardi RM, Arantes RM, Rosa CA, Neves MJ, Nicoli JR. Screening of yeasts as probiotic based on capacities to colonize the gastrointestinal tract and to protect against enteropathogen challenge in mice. J Gen Appl Microbiol. 2005;51:83–92. doi: 10.2323/jgam.51.83.CrossRefPubMedGoogle Scholar
  13. 13.
    Correa NB, Peret Filho LA, Penna FJ, Lima FM, Nicoli JR. A randomized formula controlled trial of Bifidobacterium lactis and Streptococcus thermophilus for prevention of antibiotic-associated diarrhea in infants. J Clin Gastroenterol. 2005;39:385–389. doi: 10.1097/01.mcg.0000159217.47419.5b.CrossRefPubMedGoogle Scholar
  14. 14.
    Canani RB, Cirillo P, Terrin G, et al. Probiotics for treatment of acute diarrhoea in children: randomised clinical trial of five different preparations. BMJ. 2007;335:340–345. doi: 10.1136/bmj.39272.581736.55.CrossRefPubMedGoogle Scholar
  15. 15.
    Drisko JA, Giles CK, Bischoff BJ. Probiotics in health maintenance and disease prevention. Altern Med Rev. 2003;8:143–155.PubMedGoogle Scholar
  16. 16.
    Hickson M, D’Souza AL, Muthu N, et al. Use of probiotic Lactobacillus preparation to prevent diarrhoea associated with antibiotics: randomised double-blind placebo controlled trial. BMJ. 2007;335:80–84. doi: 10.1136/bmj.39231.599815.55.CrossRefPubMedGoogle Scholar
  17. 17.
    Whelan K. Enteral-tube-feeding diarrhoea: manipulating the colonic microbiota with probiotics and prebiotics. Proc Nutr Soc. 2007;66:299–306. doi: 10.1017/S0029665107005551.CrossRefPubMedGoogle Scholar
  18. 18.
    Sazawal S, Hiremath G, Dhingra U, Malik P, Deb S, Black RE. Efficacy of probiotics in prevention of acute diarrhoea: a meta-analysis of masked, randomised placebo-controlled trials. Lancet Infect Dis. 2006;6:374–382.CrossRefPubMedGoogle Scholar
  19. 19.
    De Simone C, Vesely R, Bianchi BS, Jirillo E. The role of probiotics in modulation of the immune system in man and in animals. Int J Immunother. 1993;9:23–28.Google Scholar
  20. 20.
    Ericsson CD. Nonantimicrobial agents in the prevention and treatment of traveler’s diarrhea. Clin Infect Dis. 2005;41:557–563. doi: 10.1086/432952.CrossRefGoogle Scholar
  21. 21.
    Hilton E, Kolakowski P, Singer G, Smith M. Efficacy of Lactobacillus GG as a diarrheal preventive in travellers. J Travel Med. 1997;4:41–43. doi: 10.1111/j.1708-8305.1997.tb00772.x.CrossRefPubMedGoogle Scholar
  22. 22.
    Marteau PR, De Vrese M, Cellier CJ, Schrezenmeir J. Protection from gastrointestinal diseases with the use of probiotics. Am J Clin Nutr. 2001;73:430–436.Google Scholar
  23. 23.
    Saavedra J. Probiotics and infectious diarrhea. Am J Gastroenterol. 2000;95:16–18. doi: 10.1016/S0002-9270(99)00811-4.CrossRefGoogle Scholar
  24. 24.
    Montalto M, Arancio F, Izzi D, et al. Probiotics: history, definition, requirements and possible therapeutic applications. Ann Ital Med Int. 2002;17:157–165.PubMedGoogle Scholar
  25. 25.
    Fooks LJ, Gibson GR. Probiotics as modulators of the gut flora. Br J Nutr. 2002;88:39–49. doi: 10.1079/BJN2002628.CrossRefGoogle Scholar
  26. 26.
    Vanderhoof JA, Young RJ. The role of probiotics in the treatment of intestinal infections and inflammation. Curr Opin Gastroenterol. 2001;17:58–62. doi: 10.1097/00001574-200101000-00011.CrossRefPubMedGoogle Scholar
  27. 27.
    Lee SK, Kim HJ, Chi SG, et al. Saccharomyces boulardii activates expression of peroxisome proliferator-activated receptor-gamma in HT-29 cells. Korean J Gastroenterol. 2005;45:328–334.PubMedGoogle Scholar
  28. 28.
    Shanahan F. Physiological basis for novel drug therapies used to treat the inflammatory bowel diseases I. Pathophysiological basis and prospects for probiotic therapy in inflammatory bowel disease. Am J Physiol Gastrointest Liver Physiol. 2005;288:417–421. doi: 10.1152/ajpgi.00421.2004.CrossRefGoogle Scholar
  29. 29.
    Boirivant M, Trober W. The mechanism of action of probiotics. Curr Opin Gastroenterol. 2007;23:679–692. doi: 10.1097/MOG.0b013e3282f0cffc.CrossRefPubMedGoogle Scholar
  30. 30.
    Mc Farland LV. Meta-analysis of probiotics for the prevention of traveller’s diarrhea. Travel Med Infect Dis. 2007;5:97–105. doi: 10.1016/j.tmaid.2005.10.003.CrossRefGoogle Scholar
  31. 31.
    Villarruel G, Rubio DM, Lopez F, et al. Saccharomyces boulardii in acute childhood diarrhoea: a randomized, placebo-controlled study. Acta Paediatr. 2007;96:538–541. doi: 10.1111/j.1651-2227.2007.00191.x.CrossRefPubMedGoogle Scholar
  32. 32.
    Szajewska H, Skorka A, Dylag M. Meta-analysis: Saccharomyces boulardii for treating acute diarrhoea in children. Aliment Pharmacol Ther. 2007;25:257–264.PubMedCrossRefGoogle Scholar
  33. 33.
    Can M, Besirbellioglu BA, Avci IY, Beker CM, Pahsa A. Prophylactic Saccharomyces boulardii in the prevention of antibiotic-associated diarrhea: a prospective study. Med Sci Monit. 2006;12:19–22.Google Scholar
  34. 34.
    Mc Farland LV, Bernasconi P. Saccharomyces boulardii: a review of an innovative biotherapeutic agent. Microb Ecol Health Dis. 1993;6:157–171.CrossRefGoogle Scholar
  35. 35.
    Buts JP, Bernasconi P, Van Craynest MP, Maldague P, De Meyer R. Response of human and rat small intestinal mucosa to oral administration of Saccharomyces boulardii. Pediatr Res. 1986;20:192–196. doi: 10.1203/00006450-198602000-00020.CrossRefPubMedGoogle Scholar
  36. 36.
    Sougioultzis S, Simeonidis S, Bhaskar KR, et al. Saccharomyces boulardii produces a soluble anti-inflammatory factor that inhibits NF-kappaB-mediated IL-8 gene expression. Biochem Biophys Res Commun. 2006;343:69–76. doi: 10.1016/j.bbrc.2006.02.080.CrossRefPubMedGoogle Scholar
  37. 37.
    Isolauri E. Probiotics for infectious diarrhoea. Gut. 2003;52:436–437. doi: 10.1136/gut.52.3.436.CrossRefPubMedGoogle Scholar
  38. 38.
    Dahan S, Dalmasso G, Imbert V, Peyron JF, Rampal P, Czerucka D. Saccharomyces boulardii interferes with enterohemorrhagic Escherichia coli-induced signalling pathways in T84 cells. Infect Immun. 2003;71:766–773. doi: 10.1128/IAI.71.2.766-773.2003.CrossRefPubMedGoogle Scholar
  39. 39.
    Sherman PM, Johnson-Henry KC, Yeung HP, Ngo PSC, Goulet J, Tompkins TA. Probiotics reduce enterohemorrhagic Escherichia coli O157:H7- and enteropathogenic E. coli O127:H6-induced changes in polarized T84 epithelial cell monolayers by reducing bacterial adhesion and cytoskeletal rearrangements. Infect Immun. 2005;73:5183–5188. doi: 10.1128/IAI.73.8.5183-5188.2005.CrossRefPubMedGoogle Scholar
  40. 40.
    Ishida-Fujii K, Sato R, Goto S, et al. Prevention of pathogenic Escherichia coli infection in mice and stimulation of macrophage activation in rats by an oral administration of probiotic Lactobacillus casei I-5. Biosci Biotechnol Biochem. 2007;71:866–873. doi: 10.1271/bbb.60464.CrossRefPubMedGoogle Scholar
  41. 41.
    Johnson-Henry KC, Nadjafi M, Avitzur Y, et al. Amelioration of the effects of Citrobacter rodentium infection in mice by pretreatment with probiotics. J Infect Dis. 2005;191:2106–2117. doi: 10.1086/430318.CrossRefPubMedGoogle Scholar
  42. 42.
    Venkatesan N, Thiyagarajan V, Narayanan S, et al. Anti-diarrhoeal potential of Asparagus racemosus wild root extracts in laboratory animals. J Pharm Pharm Sci.. 2005;8:39–45.PubMedGoogle Scholar
  43. 43.
    Chitme HR, Chandra R, Kaushik S. Studies on anti-diarrheal activity of Calotropis giganta R.BR. in experimental animals. J Pharm Pharm Sci. 2004;7:70–75.PubMedGoogle Scholar
  44. 44.
    Uchida M, Kato Y, Matsueda K, Shoda R, Muraoka A, Yamoto S. Involvement of nitric oxide from nerves on diarrhea induced by castor oil in rats. Jpn J Pharmacol. 2000;82:168–170. doi: 10.1254/jjp.82.168.CrossRefPubMedGoogle Scholar
  45. 45.
    Aikawa N, Horikoshi K, Maeda H, Kobayashi H, Ohmori K. Antidiarrheal effects of Zaldaride maleate after oral, intravenous and subcutaneous administration to rats. Jpn J Pharmacol. 1999;81:397–400. doi: 10.1254/jjp.81.397.CrossRefPubMedGoogle Scholar
  46. 46.
    Mascolo N, Izzo AA, Barbato F, Capasso F. Inhibition of nitric oxide synthetase prevent castor oil-induced diarrhea in the rat. Br J Pharmacol. 1993;108:861–864.PubMedGoogle Scholar
  47. 47.
    Pinto A, Calignano A, Mascolo N, Autore G, Capasso F. Castor oil increases intestinal formation of platelet-activating factor and acid phosphatase release in the rat. Br J Pharmacol. 1989;96:872–874.PubMedGoogle Scholar
  48. 48.
    Aikawa N, Karasawa A. Effects of KW-5617 (Zaldaride maleate), a potent and selective calmodulin inhibitor, on secretory diarrhea and on gastrointestinal propulsion in rats. Jpn J Pharmacol. 1998;76:199–206. doi: 10.1254/jjp.76.199.CrossRefPubMedGoogle Scholar
  49. 49.
    Girard P, Pansart Y, Coppe MC, Gillardin JM. Saccharomyces boulardii inhibits water and electrolytes changes induced by castor oil in the rat colon. Dig Dis Sci. 2005;50:2183–2190. doi: 10.1007/s10620-005-3029-3.CrossRefPubMedGoogle Scholar
  50. 50.
    Girard P, Pansart Y, Lorette I, Gillardin JM. Dose-response relationship and mechanism of action of Saccharomyces boulardii in castor oil-induced diarrhea in rats. Dig Dis Sci. 2003;48:770–774. doi: 10.1023/A:1022801228938.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2009

Authors and Affiliations

  • Jean-François Bisson
    • 1
    Email author
  • Sophie Hidalgo
    • 1
  • Pascale Rozan
    • 2
  • Michaël Messaoudi
    • 3
  1. 1.ETAP-Ethologie Appliquée, Département de Cancérologie et Pathologies HumainesCentre de Recherche en Pharmacologie, Cancérologie-Pathologies Humaines et Nutrition-SantéVandœuvre-lès-NancyFrance
  2. 2.ETAP-Ethologie Appliquée, Département de Nutrition et SantéCentre de Recherche en Pharmacologie, Cancérologie-Pathologies Humaines et Nutrition-SantéVandœuvre-lès-NancyFrance
  3. 3.ETAP-Ethologie Appliquée, Département de PharmacologieCentre de Recherche en Pharmacologie, Cancérologie-Pathologies Humaines et Nutrition-SantéVandœuvre-lès-NancyFrance

Personalised recommendations